• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'

    7/17/24 8:55:11 AM ET
    $APD
    $BJ
    $COST
    $FTNT
    Major Chemicals
    Basic Materials
    Department/Specialty Retail Stores
    Consumer Discretionary
    Get the next $APD alert in real time by email

    On CNBC's “Mad Money Lightning Round,” Jim Cramer said Fortinet, Inc. (NASDAQ:FTNT) is not his favorite. He added that we own Palo Alto Networks, Inc. (NASDAQ:PANW) for the charitable trust.

    On July 11, Barclays analyst Saket Kalia maintained Fortinet with an Equal-Weight and lowered the price target from $75 to $70.

    When asked about Air Products and Chemicals, Inc. (NYSE:APD), Cramer said Linde plc (NASDAQ:LIN) is a “much better run company, and that's why Air Products isn't doing as well, and Linde's doing spectacularly.”

    On July 16, Air Products named Eric Guter as vice president of Investor Relations effective Sept. 30 succeeding Sidd Manjeshwar.

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “speculative situation where they have great science. I am never going to bet against a biotech company with great science, therefore I bless owning the stock. It's too risky for me, but it's ok if you want to be there,” he said.

    On July 1, Piper Sandler analyst Biren Amin maintained Sarepta Therapeutics with an Overweight rating and maintained a $205 price target.

    The “Mad Money” host recommended not selling Match Group, Inc (NASDAQ:MTCH) as “you've just got a very, very smart investor in there. You've got Starboard, there's been other activists there too… and Match has to make the changes that Starboard recommends.”

    Starboard Value sent a letter to Match Group's CEO, CFO, president and board of directors outlining actionable opportunities for enhancing shareholder value. Starboard Value holds a 6.6% stake in the company, making it the third-largest shareholder.

    BJ’s Wholesale Club Holdings, Inc (NYSE:BJ) is very good, Cramer said. “My problem is, why would I want the very good when I can get the best, which, of course, is Costco (NASDAQ:COST).”

    On July 11, Loop Capital analyst Laura Champine maintained BJ’s Wholesale with a Hold and raised the price target from $80 to $85.

    When asked about Toast, Inc. (NYSE:TOST), he said, “The problem with that is that you are investing in retail by doing that, and I do not want to be as exposed to retail right now, and so that's the only reason why I do not want to own the stock of Toast.”

    Toast reported robust performance for the quarter ended March 31 on May 7.

    Cramer said Teva Pharmaceutical Industries Limited (NYSE:TEVA) is ok, but he likes best of breed. i.e. Eli Lilly (NYSE:LLY).

    Teva Pharmaceutical said it will release second-quarter financial results on Wednesday, July 31.

    Viking Therapeutics, Inc. (NASDAQ:VKTX) is “terrific,” Cramer said. “I would put Royal Caribbean (NYSE:RCL) and Viking at the top of the heap. They are both excellent.”

    On June 27, Morgan Stanley analyst Michael Ulz initiated coverage on Viking Therapeutics with an Overweight rating and announced a price target of $105.

    Price Action:

    • Fortinet shares fell 0.7% to settle at $59.48 on Tuesday.
    • Teva shares fell 2.5% to close at $16.65 on Tuesday.
    • Viking shares fell 4% to settle at $57.00 during Tuesday's session.
    • BJ's Wholesale shares gained 1.4% to $91.38.
    • Toast shares gained 5.3% to settle at $27.30 on Tuesday.
    • Air Products shares gained 3% to close at $267.53 during Tuesday's session.
    • Sarepta shares fell 2.4% to close at $148.98 on Tuesday.
    • Match shares gained 7.5% to settle at $34.41 on Tuesday.

    Read Next:

    • Top 4 Risk Off Stocks You’ll Regret Missing In July

    Photo: s_bukley/Shutterstock.com

    Get the next $APD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APD
    $BJ
    $COST
    $FTNT

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Palo Alto Networks Inc.
    $PANW
    2/18/2026$230.00 → $200.00Outperform
    BMO Capital Markets
    Linde plc
    $LIN
    2/10/2026$460.00Buy → Hold
    DZ Bank
    Fortinet Inc.
    $FTNT
    2/9/2026$90.00 → $95.00Market Perform
    BMO Capital Markets
    Linde plc
    $LIN
    2/6/2026$455.00Overweight → Neutral
    Analyst
    Toast Inc.
    $TOST
    2/2/2026$42.00 → $36.00Neutral
    DA Davidson
    Fortinet Inc.
    $FTNT
    2/2/2026$85.00Sector Outperform → Sector Perform
    Scotiabank
    Fortinet Inc.
    $FTNT
    1/29/2026$100.00Neutral → Buy
    Rosenblatt
    More analyst ratings

    $APD
    $BJ
    $COST
    $FTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets reiterated coverage on Palo Alto Networks with a new price target

    BMO Capital Markets reiterated coverage of Palo Alto Networks with a rating of Outperform and set a new price target of $200.00 from $230.00 previously

    2/18/26 6:52:21 AM ET
    $PANW
    Computer peripheral equipment
    Technology

    Linde plc downgraded by DZ Bank with a new price target

    DZ Bank downgraded Linde plc from Buy to Hold and set a new price target of $460.00

    2/10/26 7:59:52 AM ET
    $LIN
    Major Chemicals
    Basic Materials

    $APD
    $BJ
    $COST
    $FTNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wilhelmsen Arne Alexander sold $65,426,312 worth of shares (206,442 units at $316.92) (SEC Form 4)

    4 - ROYAL CARIBBEAN CRUISES LTD (0000884887) (Issuer)

    2/20/26 4:41:02 PM ET
    $RCL
    Marine Transportation
    Consumer Discretionary

    EVP, Chief Financial Officer Felice Laura L. sold $881,580 worth of shares (8,400 units at $104.95), decreasing direct ownership by 9% to 80,074 units (SEC Form 4)

    4 - BJ's Wholesale Club Holdings, Inc. (0001531152) (Issuer)

    2/19/26 4:20:27 PM ET
    $BJ
    Department/Specialty Retail Stores
    Consumer Discretionary

    EVP, Chief People Officer Dozier Eric gifted 481 shares, decreasing direct ownership by 3% to 14,455 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    2/19/26 4:18:48 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APD
    $BJ
    $COST
    $FTNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

    Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound®Zepbound patients can access all doses in either multi-dose KwikPen or single-dose vial at the same self-pay price, starting at $299, available by prescription now through LillyDirect*INDIANAPOLIS, Feb. 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that delivers a full month of treatment in one device. With the Zepbound KwikPen, Lilly is expanding choice and helping ensure patients and

    2/23/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

    Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological conditions as it drives forward its Pivot to Growth strategy PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of

    2/20/26 2:43:11 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    $APD
    $BJ
    $COST
    $FTNT
    SEC Filings

    View All

    SEC Form SC TO-I filed by Palo Alto Networks Inc.

    SC TO-I - Palo Alto Networks Inc (0001327567) (Subject)

    2/19/26 4:24:25 PM ET
    $PANW
    Computer peripheral equipment
    Technology

    SEC Form 10-K filed by Toast Inc.

    10-K - Toast, Inc. (0001650164) (Filer)

    2/18/26 4:30:47 PM ET
    $TOST
    EDP Services
    Technology

    Palo Alto Networks Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Palo Alto Networks Inc (0001327567) (Filer)

    2/17/26 4:14:09 PM ET
    $PANW
    Computer peripheral equipment
    Technology

    $APD
    $BJ
    $COST
    $FTNT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $APD
    $BJ
    $COST
    $FTNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Lamba Sanjiv bought $999,634 worth of Ordinary Shares (2,520 units at $396.68), increasing direct ownership by 3% to 90,794 units (SEC Form 4)

    4 - LINDE PLC (0001707925) (Issuer)

    12/8/25 3:26:43 PM ET
    $LIN
    Major Chemicals
    Basic Materials

    Director Evans Andrew W bought $1,475 worth of shares (5 units at $294.96) and sold $1,416 worth of shares (5 units at $283.20) (SEC Form 4)

    4 - Air Products & Chemicals, Inc. (0000002969) (Issuer)

    11/21/25 10:14:42 AM ET
    $APD
    Major Chemicals
    Basic Materials

    Chief Executive Officer Rascoff Spencer M bought $445,691 worth of shares (14,000 units at $31.84), increasing direct ownership by 9% to 165,128 units (SEC Form 4)

    4 - Match Group, Inc. (0000891103) (Issuer)

    11/20/25 4:15:48 PM ET
    $MTCH
    Computer Software: Programming Data Processing
    Technology

    $APD
    $BJ
    $COST
    $FTNT
    Leadership Updates

    Live Leadership Updates

    View All

    Match Group Announces Manuel Bronstein and Raina Moskowitz to Join Board of Directors

    LOS ANGELES, Feb. 17, 2026 /PRNewswire/ -- Match Group (NASDAQ:MTCH) announced today that seasoned technology executives Manuel Bronstein and Raina Moskowitz are expected to join the Company's Board of Directors in connection with the 2026 Annual Meeting of Stockholders. Bronstein and Moskowitz were identified through a deliberate and thorough search process. "As we continue to strengthen the skills and expertise represented on our Board to support Match Group's growth and success, I am pleased to welcome Raina and Manuel and look forward to their insights and contributions," sa

    2/17/26 9:20:00 AM ET
    $MTCH
    Computer Software: Programming Data Processing
    Technology

    Royal Caribbean Group Appoints Christopher J. Wiernicki to Board of Directors

    MIAMI, Feb. 17, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE:RCL) today announced the appointment of Christopher J. Wiernicki, former Chairman & CEO, American Bureau of Shipping (ABS), to its Board of Directors, effective immediately. Wiernicki brings more than four decades of commercial, government and international experience in marine and offshore design, along with operations, infrastructure and safety management, ports and bunkering, digitalization, cyber security, and clean energy transition expertise.During his fourteen-year tenure at the helm of ABS, a global leader

    2/17/26 8:27:00 AM ET
    $RCL
    Marine Transportation
    Consumer Discretionary

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APD
    $BJ
    $COST
    $FTNT
    Financials

    Live finance-specific insights

    View All

    Toast Announces Fourth Quarter and Full Year 2025 Financial Results

    Added a record 30,000 net locations in 2025, including approximately 8,000 in the fourth quarter Annualized recurring run-rate (ARR) increased 26% to over $2.0 billion as of December 31, 2025 Fourth quarter net income was $101 million and Adjusted EBITDA was $163 million Toast's Board of Directors authorized a $500 million increase to share repurchase program Toast (NYSE:TOST), the all-in-one digital technology platform built for hospitality, today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 was a strong year for Toast, adding a record 30,000 net locations, growing recurring gross profit1 33%, and delivering Adjusted EBITDA margins of 3

    2/12/26 4:05:00 PM ET
    $TOST
    EDP Services
    Technology

    Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

    Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full EnrollmentVK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 MillionSAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended

    2/11/26 4:16:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After register

    2/11/26 8:30:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APD
    $BJ
    $COST
    $FTNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.

    SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    11/14/24 4:30:54 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Toast Inc.

    SC 13G - Toast, Inc. (0001650164) (Subject)

    11/14/24 1:22:38 PM ET
    $TOST
    EDP Services
    Technology

    SEC Form SC 13G filed by Royal Caribbean Cruises Ltd.

    SC 13G - ROYAL CARIBBEAN CRUISES LTD (0000884887) (Subject)

    11/13/24 12:49:26 PM ET
    $RCL
    Marine Transportation
    Consumer Discretionary